Publication:
Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia

Thumbnail Image

Open/View Files

Date

2016

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Cold Spring Harbor Laboratory Press
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Lacy, Jessica N., Jacob C. Ulirsch, Rachael F. Grace, Meghan C. Towne, John Hale, Narla Mohandas, Samuel E. Lux, Pankaj B. Agrawal, and Vijay G. Sankaran. 2016. “Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia.” Cold Spring Harbor Molecular Case Studies 2 (4): a000885. doi:10.1101/mcs.a000885. http://dx.doi.org/10.1101/mcs.a000885.

Research Data

Abstract

Whole-exome sequencing is increasingly used for diagnosis and identification of appropriate therapies in patients. Here, we present the case of a 3-yr-old male with a lifelong and severe transfusion-dependent anemia of unclear etiology, despite an extensive clinical workup. Given the difficulty of making the diagnosis and the potential side effects from performing interventions in patients with a congenital anemia of unknown etiology, we opted to perform whole-exome sequencing on the patient and his parents. This resulted in the identification of homozygous loss-of-function mutations in the EPB41 gene, encoding erythrocyte protein band 4.1, which therefore causes a rare and severe form of hereditary elliptocytosis in the patient. Based on prior clinical experience in similar patients, a surgical splenectomy was performed that resulted in subsequent transfusion independence in the patient. This case illustrates how whole-exome sequencing can lead to accurate diagnoses (and exclusion of diagnoses where interventions, such as splenectomy, would be contraindicated), thereby resulting in appropriate and successful therapeutic intervention—a major goal of precision medicine.

Description

Keywords

chronic hemolytic anemia, congenital hemolytic anemia

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories